Life Sciences & Healthcare

We provide highly specialized and multidisciplinary legal advisory services to companies leading innovation and development in the sector. We work side by side with pharmaceutical companies, biotechnology companies, CROs, medtechs, medical device manufacturers, vaccine developers, healthtechs, healthcare service providers, and precision and preventive medicine, among other key players in the sector. Our team combines deep technical and legal knowledge with solid practical experience, understanding the complex regulatory, commercial, and technological nuances that impact each segment

By continuously adopting advanced technology and sophisticated sustainability practices, and by working proactively to improve patient access to vital products, services, and solutions, this industry occupies an unquestionably relevant position in the global economy

Our view on the industry

The emergence of new technologies is driving the market toward a comprehensive and irreversible metamorphosis. Noteworthy are the rapid advances in digitalization and the emergence of new commercial paradigms in medical technology and the pharmaceutical sector.

Innovative therapies, such as cell and gene therapy, as well as medtechs, are expected to continue generating exciting news in this field. Venture capital remains fundamental to the development of the sector, while collaborative ventures and peer licensing agreements are emerging as promising investment avenues. Meanwhile, market dynamics remain volatile, driven by shifts in capital flows, geopolitics, global inflationary pressures, and economic uncertainties. Sector-specific issues, such as competition for talent, the politicization of drug prices, the judicialization of healthcare, the diversification of clinical trials, and the growing pressure to demonstrate commitment to ESG matters, also make the horizon difficult to see with the necessary clarity.

Even so, the truth is that the coming years hold great potential. We are seeing a growing number of transactions, advances in innovative therapies and medical technologies, and a strategic landscape noteworthy for its B2B collaborations, licensing agreements, and divestitures. An increased focus on contractual arrangements within supply networks further highlights the industry's ethos of resilience. Successfully navigating this dynamic terrain requires skillful maneuvering and experience in the face of constantly evolving challenges.

China
Venture capital essential for financing the sector
Small/mid-sized transactions (rather than megatransactions)
Divestiture of non-core business assets
Strategic B2B partnerships
Regulatory convergence
Innovative therapies, such as cell and gene therapy
Generative AI
Medtechs
Carbon Market
Post-pandemic market correction, requiring a continuous cycle of experimentation, learning, and action

High volatility and macroeconomic pressures
Sustainability
Financial returns in emerging markets
Loss of revenue due to patent expiration or generic competition
Rising R&D costs
Strict oversight of price controls and the entry of generics or biosimilars
Judicialization of healthcare

International Collaboration in Healthcare, with China leading the way
Clinical research, in an effort to offset the loss of market share due to the expiration of patent periods
Patient data interoperability / Real-World Data (RWD)
Precision Medicine
Preventive Medicine
Wearable technology / Health gadgets

Work Highlights

New horizons in gene and oncology therapy research in Brazil

We played a key role in providing specialized guidance to a prominent U.S. biopharmaceutical company, working closely on the development of corporate strategies, the establishment of strategic partnerships, and ensuring regulatory compliance in the innovative gene and oncology therapy clinical trials conducted in Brazil

Expanded access to medicines for rare diseases

As leaders in regulation, we worked on the development of initiatives designed to expand access to medicines for rare diseases on behalf of one of the leading global pharmaceutical companies. We refined market entry strategies, forged strategic alliances, and implemented measures to significantly improve the availability of these vital treatments in Brazil

Defining responsible Generative AI policies

In partnership with a global pharmaceutical giant, we played an important role in formulating ethical and regulatory policies to guide the responsible use of generative artificial intelligence. We sought to ensure regulatory compliance and promote the ethical use of this innovative technology across all of its operations, establishing clear and transparent guidelines

Guiding the deployment of healthcare solutions in Brazil

We facilitated the expansion of a leading infection prevention solutions company in the healthcare sector into the Brazilian market. By providing specialized guidance in areas such as asset acquisition, tax strategies, regulatory compliance, customer management, and operational structuring, we helped ensure a successful and sustainable entry into the local market

Carbon neutrality on behalf of health and well-being

We collaborated with a major investment fund and a Brazilian company committed to the energy transition, health, and well-being. Our work aims to drive the decarbonization journey, developing and implementing innovative programs for the generation and offsetting of carbon credits, aligned with the principles of sustainability and regeneration

Areas of Practice

Read our insights

LC 235/2026 traz novas medidas tributárias para combustíveis, biocombustíveis, agronegócio e fertilizantes

A Lei Complementar 235/2026 já está em vigor e representa um dos mais significativos pacotes de reforma fiscal do ano. Em nosso mais recente Tax Talk, analisamos suas principais disposições, incluindo um novo mecanismo de compensação de receitas que viabiliza reduções nos tributos federais sobre combustíveis, salvaguardas para proteger a competitividade dos biocombustíveis, arranjos de compensação de créditos de PIS/COFINS para produtores de etanol e um programa plurianual de incentivos para projetos de fertilizantes no valor de até R$ 1 bilhão por ano. As regulamentações infralegais definirão como essas medidas serão aplicadas na prática e como as organizações devem se preparar.

StandUp2Health Journal - Agosto 26

Agosto testou a capacidade de resposta do setor de Life Sciences & Healthcare. Em um único mês, o Brasil redesenhou regras de precificação no SUS, acelerou a Assistência Farmacêutica em Oncologia (AF-Onco) e viu a Anvisa abrir frentes simultâneas em publicidade, e-commerce farmacêutico, pesquisa clínica e inovação regulatória. Em paralelo, saúde digital e inteligência artificial ganharam tração concreta, enquanto movimentos de mercado e avanços terapêuticos sinalizaram uma realidade que já não se pode ignorar, que regulação, acesso e estratégia empresarial operam hoje como engrenagens de um mesmo sistema.

Caráter estratégico de projetos na Lei Geral de Licenciamento pode virar peça-chave para descarbonização

O licenciamento ambiental brasileiro ganhou uma nova pergunta central. E ela não é sobre quais projetos serão aprovados mais rápido, mas sobre quais o país decide chamar de estratégicos. Instituída pelo Decreto nº 12.673/2025 no âmbito do Conselho de Governo, a CAEE poderá propor quais empreendimentos serão qualificados como estratégicos e, assim, elegíveis à Licença Ambiental Especial, rito com prazo máximo de 12 meses para análise e conclusão do processo de licenciamento, nos termos da Lei nº 15.300/2025.

Radar Ambiental: limites da intervenção judicial na conversão de multa ambiental: STJ afeta Tema Repetitivo nº 1447

O Superior Tribunal de Justiça afetou ao regime dos recursos repetitivos a controvérsia sobre os limites da intervenção judicial na conversão de multas ambientais em prestação de serviços, registrada como Tema Repetitivo nº 1447. A Corte decidirá se a substituição da multa por medidas alternativas está no âmbito exclusivo da discricionariedade do órgão ambiental ou se o Poder Judiciário pode determinar a conversão em determinadas hipóteses. A definição terá efeito vinculante e poderá produzir impactos diretos na atuação dos órgãos ambientais e na estratégia processual dos autuados.

Get to know our leaders

Bruna Rocha

Partner

Eugénie Caroit

Counsel

Jessica Filka

Counsel

Register

and receive our content firsthand